CA3048908A1 - Targeted doxorubicin-gold nanoconjugates for tumor therapy - Google Patents

Targeted doxorubicin-gold nanoconjugates for tumor therapy Download PDF

Info

Publication number
CA3048908A1
CA3048908A1 CA3048908A CA3048908A CA3048908A1 CA 3048908 A1 CA3048908 A1 CA 3048908A1 CA 3048908 A CA3048908 A CA 3048908A CA 3048908 A CA3048908 A CA 3048908A CA 3048908 A1 CA3048908 A1 CA 3048908A1
Authority
CA
Canada
Prior art keywords
nanoconjugate
cancer
dtdtpa
doxorubicin
thioctic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3048908A
Other languages
English (en)
French (fr)
Inventor
Raghuraman Kannan
Ajit ZAMBRE
Anandhi UPENDRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri St Louis
Original Assignee
University of Missouri St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri St Louis filed Critical University of Missouri St Louis
Publication of CA3048908A1 publication Critical patent/CA3048908A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3048908A 2017-01-09 2018-01-09 Targeted doxorubicin-gold nanoconjugates for tumor therapy Pending CA3048908A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444114P 2017-01-09 2017-01-09
US62/444,114 2017-01-09
PCT/US2018/012882 WO2018129501A1 (en) 2017-01-09 2018-01-09 Targeted doxorubicin-gold nanoconjugates for tumor therapy

Publications (1)

Publication Number Publication Date
CA3048908A1 true CA3048908A1 (en) 2018-07-12

Family

ID=62791162

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3048908A Pending CA3048908A1 (en) 2017-01-09 2018-01-09 Targeted doxorubicin-gold nanoconjugates for tumor therapy

Country Status (12)

Country Link
US (1) US20210015944A1 (OSRAM)
EP (1) EP3568694B1 (OSRAM)
JP (1) JP7017258B2 (OSRAM)
KR (1) KR102568577B1 (OSRAM)
CN (1) CN110178028B (OSRAM)
AU (1) AU2018205349B2 (OSRAM)
BR (1) BR112019013469A2 (OSRAM)
CA (1) CA3048908A1 (OSRAM)
ES (1) ES2912286T3 (OSRAM)
MX (1) MX2019008233A (OSRAM)
WO (1) WO2018129501A1 (OSRAM)
ZA (1) ZA201904736B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887421B1 (ko) * 2016-09-20 2018-08-13 김문혜 체인 구동형 유기질비료 발효 건조장치
CN113797353B (zh) * 2020-06-12 2023-10-20 南京工业大学 一种放化疗联合治疗试剂及其制备方法
CN112494660B (zh) * 2020-12-22 2023-11-21 上海交通大学 纳米靶向药物的制备方法及在治疗胃癌中的应用
EP4526067A4 (en) 2022-05-17 2026-03-25 Us Gov Sec Navy GERM-FREE SYNTHESIS OF ANISOTROPIC GOLD NANOFLOWERS FOR CELL CONTROL AND DRUG DELIVERY APPLICATIONS
WO2023242766A1 (en) 2022-06-15 2023-12-21 Alembic Pharmaceuticals Limited Gold nanoconjugates
CN120713846B (zh) * 2025-07-14 2026-03-31 湖南省妇幼保健院 基于铜离子和多柔比星的纳米级配位聚合物NP@DoxCu及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563360A (zh) * 2006-10-20 2009-10-21 益普生制药两合公司 肽-细胞毒性缀合物
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
WO2010014812A2 (en) * 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Peptide compositions and methods of use
KR101196667B1 (ko) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
US9605304B2 (en) * 2011-07-20 2017-03-28 The Hong Kong Polytechnic University Ultra-stable oligonucleotide-gold and-silver nanoparticle conjugates and method of their preparation
WO2014130429A2 (en) * 2013-02-19 2014-08-28 National Health Research Institutes Caged platinum nanoclusters for anticancer chemotherapeutics
HUE050462T2 (hu) * 2013-12-30 2020-12-28 Univ Missouri Au többkomponensû nanoanyagok és szintézis eljárások

Also Published As

Publication number Publication date
AU2018205349B2 (en) 2022-09-29
RU2019125167A (ru) 2021-02-09
AU2018205349A1 (en) 2019-06-27
MX2019008233A (es) 2019-10-17
ES2912286T3 (es) 2022-05-25
EP3568694A1 (en) 2019-11-20
CN110178028B (zh) 2021-04-27
CN110178028A (zh) 2019-08-27
EP3568694A4 (en) 2020-12-30
RU2019125167A3 (OSRAM) 2021-09-13
KR20190104333A (ko) 2019-09-09
US20210015944A1 (en) 2021-01-21
ZA201904736B (en) 2021-04-28
BR112019013469A2 (pt) 2020-01-07
WO2018129501A1 (en) 2018-07-12
JP7017258B2 (ja) 2022-02-08
EP3568694B1 (en) 2022-02-16
KR102568577B1 (ko) 2023-08-18
JP2020504130A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
AU2018205349B2 (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
Botella et al. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation
Bai et al. A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: An in vitro study of targeted delivery of cisplatin to ovarian cancer cells
Liu et al. Covalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy
EP2210616A1 (en) Multifunctional stealth nanoparticles for biomedical use
Gu et al. A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia
Zhan et al. A new targeted delivery approach by functionalizing drug nanocrystals through polydopamine coating
Dutta et al. Gelatin grafted Fe3O4 based curcumin nanoformulation for cancer therapy
Jain et al. pH dependent drug release from drug conjugated PEGylated CdSe/ZnS nanoparticles
Song et al. Redox-responsive amphipathic dextran nanomicelles for solid tumor therapy
Dharmatti et al. Surface orchestration of gold nanoparticles using cysteamine as linke r and folate as navigating molecule for synaphic delivery of doxorubicin
Iqbal et al. A bioinspired doxorubicin-carried albumin Nanocage against aggressive Cancer via systemic targeting of tumor and lymph node metastasis
Xue et al. Anti-tumor efficacy of polymer–platinum (II) complex micelles fabricated from folate conjugated PEG-graft-α, β-poly [(N-amino acidyl)-aspartamide] and cis-dichlorodiammine platinum (II) in tumor-bearing mice
Rahiminezhad et al. PLGA-graphene quantum dot nanocomposites targeted against αvβ3 integrin receptor for sorafenib delivery in angiogenesis
CN110167530A (zh) 基于纳米粒子的肝靶向治疗
Liu et al. Folic acid functionalized γ-Cyclodextrin C60, a novel vehicle for tumor-targeted drug delivery
Zhang et al. Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy
JP5873719B2 (ja) 白金含有化合物被覆ナノ粒子を含有するコンジュゲート
Liang et al. Vitamin E-based redox-sensitive salinomycin prodrug-nanosystem with paclitaxel loaded for cancer targeted and combined chemotherapy
Xiao et al. Versatile hydrogel drug carrier loading with peptide-carbon dots conjugates for efficient targeting and synergistic suppression of breast cancer cell
Shi et al. Enhanced legumain-recognition and NIR controlled released of cisplatin-indocyanine nanosphere against gastric carcinoma
Li et al. Carboxymethyl chitosan-modified folate-targeted carbon nanotubes-baicalin complexes for cancer progression and metastasis
Uttekar et al. 1, 2-Dihexadecanoyl-sn-glycero-3-phosphoethanolamin (DPPE), doxorubicin and folic acid conjugated micelles for cancer management in tumor bearing BALB/c mice
US20100021471A1 (en) Carbon nanotube-based drug delivery systems and methods of making same
RU2773707C2 (ru) Наноконъюгаты доксорубицин-золото направленного воздействия для терапии опухолей

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230109

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250909

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250915

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226